Top

Published in:

01-12-2011

Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer

Authors: Naveena B. Janakiram, Altaf Mohammed, Chinthalapally V. Rao

Published in: Cancer and Metastasis Reviews | Issue 3-4/2011

Abstract

Unresolved inflammation, due to insufficient production of proresolving anti-inflammatory lipid mediators, can lead to an increased risk of tumorigenesis and tumor cell invasiveness. Various bioactive lipids, particularly those formed by cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, have been well established as therapeutic targets for many epithelial cancers. Emerging studies suggest that there is a role for anti-inflammatory bioactive lipids and their mediators during the resolution phase of inflammation. These proresolving bioactive lipids, including lipoxins (LXs) and resolvins (RVs), have potent anti-inflammatory and anti-carcinogenic properties. The molecular signaling pathways controlling generation and degradation of the proresolving mediators LXs and RVs are now being elucidated, and the component molecules may serve as new targets for regulation of inflammation and inflammation-associated cancers like colon and pancreatic cancers. This review will highlight the recent advances in our understanding of how these bioactive lipids and proresolving mediators may function with various immune cells and cytokines in inhibiting tumor cell proliferation and progression and invasiveness of colon and pancreatic cancers.

Tenesa, A., & Dunlop, M. G. (2009). New insights into the etiology of colorectal cancer from genome-wide association studies. Nature Reviews Genetics, 10, 353–358.PubMed

Jemal, A., Center, M. M., Ward, E., & Thun, M. J. (2009). Cancer occurrence. Methods in Molecular Biology, 471, 3–29.PubMed

Jemal, A., Siegel, R., Ward, E., et al. (2008). Cancer statistics. CA: A Cancer Journal for Clinicians, 58, 71–96.

Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539–545.PubMed

Algül, H., Treiber, M., Lesina, M., & Schmid, R. M. (2007). Mechanisms of disease: chronic inflammation and cancer in the pancreas—a potential role for pancreatic stellate cells? Nature Clinical Practice. Gastroenterology & Hepatology, 4, 454–462.

Whitcomb, D. C., Gorry, M. C., Preston, R. A., Furey, W., Sossenheimer, M. J., Ulrich, C. D., et al. (1996). Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genetics, 14, 141–145.PubMed

Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000). Genetic progression in the pancreatic ducts. American Journal of Pathology, 156, 1821–1825.PubMed

Raimondi, S., Maisonneuve, P., & Lowenfels, A. B. (2009). Epidemiology of pancreatic cancer: an overview. Nature Reviews. Gastroenterology & Hepatology, 6, 699–708.

Greer, J. B., & Whitcomb, D. C. (2009). Inflammation and pancreatic cancer: an evidence-based review. Current Opinion in Pharmacology, 9, 411–418.PubMed

10.

Serhan, C. N. (1997). Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL). Prostaglandins, 53, 107–137.PubMed

11.

Maitra, A., Ashfaq, R., Gunn, C. R., Rahman, A., Yeo, C. J., Sohn, T. A., et al. (2002). Cyclooxygenase-2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. American Journal of Clinical Pathology, 118, 194–201.PubMed

12.

Rao, C. V., & Reddy, B. S. (2004). NSAIDs and chemoprevention. Current Cancer Drug Targets, 4, 29–42.PubMed

13.

Castellone, M. D., Teramoto, H., & Gutkind, J. S. (2006). Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Research, 66, 11085–11088.PubMed

14.

Dorsam, R. T., & Gutkind, J. S. (2007). G-protein-coupled receptors and cancer. Nature Reviews. Cancer, 7, 79–94.PubMed

15.

Cherukuri, D. P., Chen, X. B. O., Goulet, A., et al. (2007). The EP₄ receptor antagonist, L-161,982, blocks prostaglandin E₂-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Experimental Cell Research, 313, 2969–2979.PubMed

16.

Murata, T., Lin, M. I., Aritake, K., et al. (2008). Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proceedings of the National Academy of Sciences, 105(50), 20009–20014.

17.

Backlund, M. G., Mann, J. R., Holla, V. R., et al. (2005). 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. Journal of Biological Chemistry, 280(5), 3217–3223.PubMed

18.

Molina, M. A., Sitja-Amau, M., Lemoine, M. G., Frazier, M., & Sinicrope, F. A. (1999). Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Research, 59, 4356–4362.PubMed

19.

Okami, J., Yamamoto, H., Fujiwara, Y., Tsujie, M., Kondo, K., Noura, S., et al. (1999). Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clinical Cancer Research, 5, 2018–2024.PubMed

20.

Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., et al. (1999). Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research, 59, 987–990.PubMed

21.

Niijima, M., Yamaguchi, T., Ishihara, T., et al. (2002). Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer, 94, 1565–1573.PubMed

22.

Bergmann, F., Breinig, M., Hopfner, M., et al. (2009). Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? American Journal of Gastroenterology, 104, 171–181.PubMed

23.

Hermanova, M., Karasek, P., Nenutil, R., et al. (2009). Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma. Pancreas, 38, 565–571.PubMed

24.

Levitt, R. J., & Pollak, M. (2002). Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Research, 62, 7372–7376.PubMed

25.

Pold, M., Krysan, K., Pold, A., Dohadwala, M., Heuze-Vourc’h, N., Mao, J. T., et al. (2004). Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Research, 64, 6549–6555.PubMed

26.

Stoeltzing, O., Liu, W., Fan, F., Wagner, C., Stengel, K., Somcio, J. R., et al. (2007). Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. Cancer Letters, 258(2), 291–300.PubMed

27.

Rao, C.V., Mohammed, A., Janakiram, N., Qian, L., Choi, C., Zhang, Y., Lightfoot, Stan., Steele, V.E. (2009). Delayed progression of pancreatic carcinoma in a conditional K-rasG12D mice by nitric oxide (NO)-releasing aspirin. In 100 ^th AACR annual meeting, Apr; #2062.

28.

Tong, W. G., Ding, X. Z., Hennig, R., Witt, R. C., Standop, J., Pour, P. M., et al. (2002). Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clinical Cancer Research, 8, 3232–3242.PubMed

29.

Ohd, J. F., Nielsen, C. K., Campbell, J., Landberg, G., Lofberg, H., & Sjolander, A. (2003). Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology, 124, 57–70.PubMed

30.

Hayashi, T., Nishiyama, K., & Shirahama, T. (2006). Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. International Journal of Urology, 13, 1086–1091.PubMed

31.

Zhi, H., Zhang, J., Hu, G., Lu, J., Wang, X., Zhou, C., et al. (2003). The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. International Journal of Cancer, 106, 327–333.

32.

Yoshimura, R., Matsuyama, M., Tsuchida, K., Kawahito, Y., Sano, H., & Nakatani, T. (2003). Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. Journal of Urology, 170, 1994–1999.PubMed

33.

Qiao, L., Kozoni, V., Tsioulias, G. J., Koutsos, M. I., Hanif, R., Shiff, S. J., et al. (1995). Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochimica et Biophysical Acta, 1258, 215–223.

34.

Bortuzzo, C., Hanif, R., Kashfi, K., Staiano-Coico, L., Shiff, S. J., Rigas, B., et al. (1996). The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochimica et Biophysical Acta, 1300, 240–246.

35.

Avis, I., Hong, S. H., Martinez, A., Moody, T., Choi, Y. H., Trepel, J., et al. (2001). Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. Journal of the Federation of American Societies for Experimental Biology, 15, 2007–2009.

36.

Ding, X. Z., Tong, W. G., & Adrian, T. E. (2003). Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer. Oncology, 65, 285–294.PubMed

37.

Tong, W. G., Ding, X. Z., Talamonti, M. S., Bell, R. H., & Adrian, T. E. (2005). LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochemical Biophysical Research Communication, 335, 949–956.

38.

Hong, S. H., Avis, I., Vos, M. D., Martinez, A., Treston, A. M., & Mulshine, J. L. (1999). Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Research, 59, 2223–2228.PubMed

39.

Hennig, R., Ding, X. Z., Tong, W. G., Schneider, M. B., Standop, J., Friess, H., et al. (2002). 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. American Journal of Pathology, 161, 421–428.PubMed

40.

Ding, X. Z., Talamonti, M. S., Bell, R. H., Jr., & Adrian, T. E. (2005). A novel anti-pancreatic cancer agent, LY293111. Anti-Cancer Drugs, 16, 467–473.PubMed

41.

Tong, W. G., Ding, X. Z., Talamonti, M. S., Bell, R. H., & Adrian, T. E. (2007). Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. Anti-Cancer Drugs, 18, 535–541.PubMed

42.

Edderkaoui, M., Hong, P., Vaquero, E. C., Lee, J. K., Fischer, L., Friess, H., et al. (2005). Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. American Journal of Physiology—Gastrointestinal and Liver Physiology, 289, G1137–G1147.PubMed

43.

Melstrom, L. G., Bentrem, D. J., Salabat, M. R., Kennedy, T. J., Ding, X. Z., Strouch, M., et al. (2008). Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clinical Cancer Research, 14, 6525–6530.PubMed

44.

Saif, M. W., Oettle, H., Vervenne, W. L., Thomas, J. P., Spitzer, G., Visseren-Grul, C., et al. (2009). Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer Journal of Clinicians, 15, 339–343.

45.

Romano, M., & Claria, J. (2003). Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. Federation of American Society for Experimental Biology, 17, 1986–1995.

46.

Byrum, R. S., Goulet, J. L., Griffiths, R. J., & Koller, B. H. (1997). Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. The Journal of Experimental Medicine, 185, 1065–1075.PubMed

47.

Griffiths, R. J., Smith, M. A., Roach, M. L., Stock, J. L., Stam, E. J., Milici, A. J., et al. (1997). Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. The Journal of Experimental Medicine, 185, 1123–1129.PubMed

48.

Goulet, J. L., Snouwaert, J. N., Latour, A. M., Coffman, T. M., & Koller, B. H. (1994). Altered inflammatory responses in leukotriene-deficient mice. Proceedings of the National Academy of Sciences, 91, 12852–12856.

49.

Peters-Golden, M., Bailie, M., Marshall, T., Wilke, C., Phan, S. H., Toews, G. B., et al. (2002). Protection from pulmonary fibrosis in leukotriene-deficient mice. American Journal of Respiratory and Critical Care Medicine, 165, 229–235.PubMed

50.

Gavett, S. H., Madison, S. L., Chulada, P. C., Scarborough, P. E., Qu, W., Boyle, J. E., et al. (1999). Allergic lung responses are increased in prostaglandin H synthase-deficient mice. Journal of Clinical Investigation, 104, 721–732.PubMed

51.

Celotti, F., & Durand, T. (2003). The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins & Other Lipid Mediators, 71, 147–162.

52.

Fiorucci, S., Meli, R., Bucci, M., & Cirino, G. (2001). Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochemical Pharmacology, 62, 1433–1438.PubMed

53.

Ding, X. Z., Iversen, P., Cluck, M. W., Knezetic, J. A., & Adrian, T. E. (1999). Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochemical and Biophysical Research Communications, 261, 218–223.PubMed

54.

Ding, X. Z., Tong, W. G., & Adrian, T. E. (2001). 12-Lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. International Journal of Cancer, 94, 630–636.

55.

Mohammed, A., Qian, L., Janakiram, N., Choi, C., Zhang, Y., Steele, V.E. Rao, C.V., (2009). Chemoprevention of colon and small intestinal tumorigenesis in ApcMin/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor. In 100 ^th AACR annual meeting, Apr; #4781.

56.

Mohammed, A., Janakiram, N., Ely, M., Lightfoot, Stan., Steele, V.E. Rao, C.V., (2011). Licofelone, a novel dual COX–LOX inhibitor prevents progression of panIN lesions to pancreatic carcinoma by targeting miRNAs and cancer stem cells in p48 Cre/+-LSL-Kras G12D transgenic mice. In 102 ^nd AACR annual meeting, Apr 2–6; #2839.

57.

Alvaro-Gracia, J. M. (2004). Licofelone—clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford, England), 43(Suppl 1), i21–i25.

58.

Chiang, N., Arita, M., & Serhan, C. N. (2005). Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 73, 163–177.PubMed

59.

Brezinski, M. E., & Serhan, C. N. (1990). Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proceedings of the National Academy of Sciences, 87, 6248–6252.

60.

Claria, J., & Serhan, C. N. (1995). Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell–leukocyte interactions. Proceedings of the National Academy of Sciences, 92, 9475–9479.

61.

Kieran, N. E., Maderna, P., & Godson, C. (2004). Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney International, 65, 1145–1154.PubMed

62.

Serhan, C. N. (2002). Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid mediators, 68–69, 4333–4455.

63.

Canny, G., Levy, O., Furuta, G. T., Narravula-Alipati, S., Sisson, R. B., Serhan, C. N., et al. (2002). Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proceedings of the National Academy of Sciences, 99, 3902–3907.

64.

Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., et al. (1995). Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry, 34(44), 14609–14615.PubMed

65.

Aliberti, J., Hieny, S., Reise, S. C., Serhan, C. N., & Sher, A. (2002). Lipoxin-mediated inhibition of interleukin-12 production by dendritic cells: a mechanism for the regulation of microbial immunity. Nature Immunology, 3, 76–82.PubMed

66.

Fierro, I. M., Colgan, S. P., Bernasconi, G., Petasis, N. A., Clish, C. B., Arita, M., et al. (2003). Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. Journal of Immunology, 170, 2688–2694.

67.

Zhou, M., Chen, B., Sun, H., Deng, Z., Andersson, R., & Zhang, Q. (2011). The protective effects of lipoxin A4 during the early phase of severe acute pancreatitis in rats. Scandinavian Journal of gasteroenterology, 46(2), 211–219.

68.

Songjun, L., Ping, W., Duyun, Y., Yinping, H., Xiaoyan, Z., Yongsheng, L., et al. (2009). Effects of lipoxin A₄ on CoCl₂-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells. Pharmacology, 84, 17–23.

69.

Bellenger, J., Bellenger, S., Bataille, A., Massey, K. A., Nicolaou, A., Rialland, M., et al. (2010). High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes, 60, 1090–1099.

70.

Cezar-de-Mello, P. F. T., Vieira, A. M., Nascimento-Silva, V., Villela, C. G., Barja-Fidalgo, C., & Fierro, I. M. (2008). ATL-1, an analogue of aspirin-triggered lipoxin A₄, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. British Journal of Pharmacology, 153(5), 956–965.PubMed

71.

Kantarci, A., Blackwood, A., Hasturk, H., Serhan, C.N., Van, T.E. Dyke. (2008). Resolvin-E1 and lipoxin-A4 control pro-inflammatory PMN functions in diabetes. In IDAR 86 ^th Periodontal Research-Pathogenesis. Poster # 2736.

72.

Gewirtz, A. T., Collier-Hyams, L. S., Young, A. N., Kucharzik, T., Guilford, W. J., Parkinson, J. F., et al. (2002). Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. Journal of Immunology, 168(10), 5260–5267.

73.

Chiang, N., Serhan, C. N., Dahle’n, S. E., Drazen, J. M., Hay, D. W., Rovati, G. E., et al. (2006). The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacology Reviews, 58, 463–487.

74.

Ye, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C., Parmentier, M., et al. (2009). International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacology Reviews, 61, 119–161.

75.

Hachicha, M., Pouliot, M., Petasis, N. A., & Serhan, C. N. (1999). Lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1_-inhibited neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. The Journal of Experimental Medicine, 189, 1923–1930.PubMed

76.

Wu, S. H., Liao, P. Y., Don, L., & Chen, Z. Q. (2008). Signal pathway involved in inhibition by lipoxin A4 of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflammation Research, 57, 430–437.PubMed

77.

Levy, B. D., Bonnans, C., Silverman, E. S., Palmer, L. J., Marigowda, G., & Israel, E. (2005). Severe Asthma Research Program, National Heart, Lung, and Blood Institute Diminished lipoxin biosynthesis in severe asthma. American Journal of Respiratory and Critical Care Medicine, 172, 824–830.PubMed

78.

Levy, B. D., Lukacs, N. W., Berlin, A. A., Schmidt, B., Guilford, W. J., Serhan, C. N., et al. (2007). Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. Journal of the Federation of American Societies for Experimental Biology, 21, 3877–3884.

79.

Fiorucci, S., Wallace, J. L., Mencarelli, A., Distrutti, E., Rizzo, G., Farneti, S., et al. (2004). A-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proceedings of National Academy of Sciences, 101, 15736–15741.

80.

Gronert, K., Gewirt, Z. A., Madara, J. L., & Serhan, C. N. (1998). Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon and inhibits tumor necrosis factor -induced IL-8 release. The Journal of Experimental Medicine, 187, 1285–1294.PubMed

81.

Kure, I., Nishiumi, S., Nishitani, Y., Tanoue, T., Ishida, T., Mizuno, M., et al. (2010). Lipoxin A4 reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-_B activation. The Journal of Pharmacology and Experimental Therapeutics, 332, 541–548.PubMed

82.

Ohkawara, T., Mitsuyama, K., Takeda, H., Asaka, M., Fujiyama, Y., & Nishihira, J. (2008). Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran sulfate sodium-induced colitis. Scandinavian Journal of Gastroenterology, 43, 1497–1504.PubMed

83.

Andrew, T., McCormick, B. G., Neish, S. A., Petasis, A. N., Gronert, K., Serhan, C. N., et al. (1998). Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. Journal of Clinical Investigations, 101, 1860–1869.

84.

Serhan, C. N., et al. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. The Journal of Experimental Medicine, 196, 1025–1037.PubMed

85.

Arita, M., et al. (2005). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proceedings of the National Academy of Sciences, 102, 7671–7676.

86.

Hudert, C. A., et al. (2006). Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proceedings of the National Academy of Sciences, 103, 11276–11281.

87.

Campbell, E. L., Louis, N. A., Tomassetti, S. E., Canny, G. O., Arita, M., Serhan, C. N., et al. (2007). Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. Federation of American Society for Experimental Biology Journal, 21, 3162–3170.

88.

Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Nishiumi, S., Masuda, A., et al. (2010). Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflammatory Bowel Disease, 16, 87–95.

89.

Campbell, L. E., MacManus, F. C., Kominsky, J. D., Keely, S., Glover, E. L., Bowers, E. B., et al. (2010). Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proceedings of the National Academy of Sciences of the United States of America, 107, 14298–14303. doi:10.1073/pnas.0914730107.PubMed

90.

Aoki, H., Hisada, T., Ishizuka, T., Utsugi, M., Kawata, T., Shimizu, Y., et al. (2008). Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochemical and Biophysical Research Communications, 367, 509–515.PubMed

91.

Nieto, N., Torres, M. I., Ríos, A., & Gil, A. (2002). Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. Journal of Nutrition, 132, 11–19.PubMed

92.

Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Nishiumi, S., Masuda, A., et al. (2009). Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflammation and Bowel Diseases, 16(1), 87–95. doi:10.1002/ibd.21029.

93.

Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., et al. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science, 296, 539–541.PubMed

94.

Lund, T., Mangsbo, S. M., Scholz, H., Gjorstrup, P., Tötterman, T. H., Korsgren, O., et al. (2010). Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro. Experiments in Clinical Endocrinology and Diabetes., 118(4), 237–244.

95.

Crawford, M., Galli, C., Visioli, F., Renaud, S., Simopoulos, A. P., & Spector, A. A. (2000). Role of plant-derived omega-3 fatty acids in human nutrition. Annals of Nutrition and Metabolism, 44, 263–265.PubMed

96.

Rose, D. P., & Connolly, J. M. (1999). Omega-3 fatty acids as cancer chemopreventive agents. Pharmacology and Therapeutics, 83, 217–244.PubMed

97.

Ringbom, T., Huss, U., Stenholm, A., et al. (2001). Cox-2 inhibitory effects of naturally occurring and modified fatty acids. Journal of Natural Products, 64, 745–749.PubMed

98.

Singh, J., Hamid, R., & Reddy, B. S. (1997). Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Research, 57, 3465–3470.PubMed

99.

Culp, B. R., Titus, B. G., & Lands, W. E. (1979). Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins and Medicine, 3, 269–278.PubMed

100.

Marshall, L. A., & Johnston, P. V. (1982). Modulation of tissue prostaglandin synthesizing capacity by increased ratios of dietary alpha-linolenic acid to linoleic acid. Lipids, 17, 905–913.PubMed

101.

Corey, E. J., Shih, C., & Cashman, J. R. (1983). Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proceedings of the National Academy of Sciences, 80, 3581–3584.

102.

Grimm, H., Mayer, K., Mayser, P., & Eigenbrodt, E. (2002). Regulatory poten Yoshimura al of n_3 fatty acids in immunological and inflammatory processes. British Journal of Nutrition, 87(suppl), S59–S67.PubMed

103.

Von Schacky, C., Kiefl, R., Marcus, A. J., Broekman, M. J., & Kaminski, W. E. (1993). Dietary n_3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes. Biochimica et Biophysica Acta, 1166, 20–24.

104.

Tsunomori, M., Fujimoto, Y., Muta, E., Nishida, H., Sakuma, S., & Fujita, T. (1996). 15-Hydroperoxyeicosapentaenoic acid inhibits arachidonic acid metabolism in rabbit platelets more potently than eicosapentaenoic acid. Biochimica et Biophysica Acta, 1300, 171–176.PubMed

105.

Collett, E. D., Davidson, L. A., Fan, Y. Y., Lupton, J. R., & Chapkin, R. S. (2001). n_6 And n_3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. American Journal of Physiology, 280, C1066–C1075.PubMed

106.

Chang, W. L., Chapkin, R. S., & Lupton, J. R. (1998). Fish oil blocks azoxymethane induced rat colon tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell proliferation. Journal of Nutrition, 128, 491–497.PubMed

107.

Murray, N. R., Weems, C., Chen, L., et al. (2002). Protein kinase C betaII and TGFbetaRII in omega-3 fatty acid-mediated inhibition of colon carcinogenesis. The Journal of Cell Biology, 157, 915–920.PubMed

108.

Murray, N. R., Davidson, L. A., Chapkin, R. S., Clay Gustafson, W., Schattenberg, D. G., & Fields, A. P. (1999). Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. The Journal of Cell Biology, 145, 699–711.PubMed

109.

Gokmen-Polar, Y., Murray, N. R., Velasco, M. A., Gatalica, Z., & Fields, A. P. (2001). Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Research, 61, 1375–1381.PubMed

110.

Roeder, C., Kalthoff, H., Henne-Bruns, D., & Kremer, B. (1995). Expression of the cytokines interleukin-113 and GM-CSF in pancreatic tumor cells is stimulated by tumor necrosis factor-et via different mechanisms. In G. Hierholzer, J. Seifert, & W. Hartel (Eds.), Chirurgisches Forum f. Experim. u. klinische Forschung (pp. 505–508). Berlin: Springer.

111.

Glick, A. B., Sporn, M. B., & Yuspa, S. H. (1991). Altered regulation of TGF-beta 1 and TGF-alpha in primary keratinocytes and papillomas expressing v-Ha-ras. Molecular Carcinogenesis, 4, 210–219.PubMed

112.

Kalthoff, H., Roeder, C., & Schmiegel, W. (1993). Cytokine-mediated regulation of growth factor receptors (EGF-R and erb-B2) in pancreatic tumors. In C. Wagener & M. Neumann (Eds.), Molecular diagnostics of cancer (pp. 175–186). Berlin: Springer.

113.

Kleeff, J., Kusama, T., Rossi, D. L., Ishiwata, T., Maruyama, H., Friess, H., et al. (1999). Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. International Journal of Cancer, 81, 650–665.

114.

Farrow, B., Sugiyama, Y., Chen, A., Uffort, E., Nealon, W., & Mark Evers, B. (2004). Inflammatory mechanisms contributing to pancreatic cancer development. Annals of Surgery, 239, 763–769.PubMed

115.

Kuwada, Y., Sasaki, T., Morinaka, K., Kitadai, Y., Mukaida, N., & Chayama, K. (2003). Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. International Journal of Oncology, 22, 765–771.PubMed

116.

Xiong, Q., Shi, Q., Le, X., Wang, B., & Xie, K. (2001). Regulation of interleukin-8 expression by nitric oxide in human pancreatic adenocarcinoma. Journal of Interferon and Cytokine Research, 21, 529–537.PubMed

117.

Muerkoster, S., Wegehenkel, K., Arlt, A., Witt, M., Sipos, B., Kruse, M. L., et al. (2004). Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Research, 64, 1331–1337.PubMed

118.

Marchesi, F., Monti, P., Leone, B. E., Zerbi, A., Vecchi, A., Piemonti, L., et al. (2004). Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Research, 64, 8420–8427.PubMed

119.

Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285–296.PubMed

120.

Becker, C., Fantini, M. C., Wirtz, S., et al. (2005). IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle, 4, 217–220.PubMed

121.

Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G. Y., Vallabhapurapu, S., et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103–113.PubMed

122.

Matsumoto, S., Hara, T., Mitsuyama, K., et al. (2010). Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. Journal of Immunology, 184, 1543–1551.

123.

Becker, C., Fantini, M. C., Schramm, C., et al. (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 21, 491–501.PubMed

124.

Ring, W. L., Riddick, C. A., Baker, J. R., Munafo, D. A., & Bigby, T. D. (1996). Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte–macrophage colony stimulating factor and interleukin-3. Journal of Clinical Investigations, 97, 1293–1301.

125.

Feltenmark, S., Runarsson, C., Larsson, P., Jakobsson, P-i, Bjorkholm, M., & Claesson, H.-E. (1995). Diverse expression of cytosolic phospholipase A2, 5-lipoxygenase and prostaglandin H synthase 2 in acute pre-B-lymphocytic leukaemia ce1is. British Journal of Haematology, 90, 585–594.PubMed

126.

Nassar, C. M., Morrow, J. D., Roberts, L. J., II, Lakkis, F. C., & Badr, K. F. (1994). Induction of l5-lipoxygenase by interleukin-13 in human blood monocytes. Journal of Biological Chemistry, 269(2763), 1–27634.

127.

Stenke, L., Reizenstein, P., & Lindgren, J. A. (1994). Leukotrienes and lipoxins—new potential performers in the regulation of human myelopoiesis. Leukemia Research, 18, 727–732.PubMed

128.

Erreni, M., Bianchi, P., Laghi, L., Mirolo, M., Fabbri, M., Locati, M., et al. (2009). Expression of chemokines and chemokine receptors in human colon cancer. Methods in Enzymology, 460, 105–121.PubMed

129.

Kollias, G. (2004). Modeling the function of tumor necrosis factor in immune pathophysiology. Autoimmunity Reviews, 3(Suppl 1), S24–S25.PubMed

130.

Grivennikov, S. I., Tumanov, A. V., Liepinsh, D. J., et al. (2005). Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity, 22, 93–104.PubMed

131.

Popivanova, B. K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S., et al. (2008). Blocking sTNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. Journal of Clinical Investigation, 118, 560–570.PubMed

132.

Prescott, S. M., Zimmerman, G. A., Stafforini, D. M., et al. (2000). Platelet-activating factor and related lipid mediators. Annual Reviews in Biochemistry, 69, 419–445.

133.

Ko, H. M., Jung, H. H., Seo, K. H., et al. (2006). Platelet-activating factor-induced NF-kappaB activation enhances VEGF expression through a decrease in p53 activity. Federation of the Societies of Biochemistry and Molecular Biology- Letters, 580, 3006–3012.

134.

Biancone, L., Cantaluppi, V., Del Sorbo, L., et al. (2003). Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clinical Cancer Research, 9, 4214–4220.PubMed

135.

Griffiths, R. J. (1999). Prostaglandins and inflammation. In J. I. Gallin & R. Snyderman (Eds.), Inflammation: basic principles and clinical correlates (pp. 249–265). Philadelphia: Lippincott & Wilkins.

136.

Dumont, P., Berton, A., Nagy, N., et al. (2008). Expression of galectin-3 in the tumor immune response in colon cancer. Laboratory Investigations, 88, 896–906.

Title: Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer
Authors: Naveena B. Janakiram
Altaf Mohammed
Chinthalapally V. Rao
Publication date: 01-12-2011
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-011-9311-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2011

Cannabinoids, endocannabinoids, and cancer

The cytochrome P450 pathway in angiogenesis and endothelial cell biology

Cyclooxygenase-2 and Gastric Cancer

Preface

Prostaglandin catabolic enzymes as tumor suppressors

The role of the EP receptors for prostaglandin E2 in skin and skin cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer